These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 32420190)

  • 1. A case of castration-resistant prostate cancer with liver metastases achieved a complete response by docetaxel chemotherapy.
    Shirotake S; Umezawa Y; Okabe T; Kaneko G; Kanao K; Nishimoto K; Oyama M
    Transl Androl Urol; 2020 Apr; 9(2):819-823. PubMed ID: 32420190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complete response with early introduction of cabazitaxel in a patient with multiple lung metastases of castration-resistant prostate cancer following the early detection of metastases using liquid biopsy: a case report.
    Kosaka T; Hongo H; Oya M
    BMC Cancer; 2019 Jun; 19(1):562. PubMed ID: 31185946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
    Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
    BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
    Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
    Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
    Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; Van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
    Eur Urol; 2011 Apr; 59(4):572-83. PubMed ID: 21315502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Role of PCA 3 as a Prognostic Factor in Patients with Castration-resistant Prostate Cancer (CRPC) Treated with Docetaxel.
    Bourdoumis A; Chrisofos M; Stasinou T; Christopoulos P; Mourmouris P; Kostakopoulos A; Deliveliotis C
    Anticancer Res; 2015 May; 35(5):3075-9. PubMed ID: 25964598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate-specific antigen response rate of sequential chemotherapy in castration-resistant prostate cancer: the results of real life practice.
    Song G; Lee C; You D; Jeong IG; Hong JH; Ahn H; Kim CS
    Prostate Int; 2013; 1(3):125-32. PubMed ID: 24223414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal PSA Threshold for Androgen-Deprivation Therapy in Patients with Prostate Cancer following Radical Prostatectomy and Adjuvant Radiation Therapy.
    Ahn HK; Lee KS; Kim D; Rha KH; Hong SJ; Chung BH; Koo KC
    Yonsei Med J; 2020 Aug; 61(8):652-659. PubMed ID: 32734728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A metastatic castration resistant prostate cancer patient with multiple bone metastases has durable biochemical and radiological response to docetaxel chemotherapy.
    Daimon T; Kosaka T; Oya M
    Am J Clin Exp Urol; 2016; 4(2):28-31. PubMed ID: 27766278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate-specific antigen kinetic profiles during androgen deprivation therapy as prognostic factors in castration-resistant prostate cancer.
    Kim M; Lee J; Jeong CW; Ku JH; Kim HH; Kwak C
    Urol Oncol; 2015 May; 33(5):203.e1-9. PubMed ID: 25726498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exponential rise in prostate-specific antigen (PSA) during anti-androgen withdrawal predicts PSA flare after docetaxel chemotherapy in patients with castration-resistant prostate cancer.
    Han KS; Hong SJ
    Yonsei Med J; 2015 Mar; 56(2):368-74. PubMed ID: 25683983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leptomeningeal Metastases in a Patient with Castration-Resistant Prostate Cancer.
    Koie T; Hashimoto Y; Suzuki Y; Hatayama Y; Kimura F
    Case Rep Urol; 2020; 2020():5627548. PubMed ID: 33005471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Predictive factor analysis of time to progression of castration-resistant prostate cancer after androgen deprivation therapy].
    Ji GJ; Huang C; Song G; Li XS; Song Y; Zhou LQ
    Beijing Da Xue Xue Bao Yi Xue Ban; 2017 Aug; 49(4):657-662. PubMed ID: 28816284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of Deferred Combined Androgen Blockade Therapy Predicts Efficacy in Abiraterone Acetate Treated Metastatic Castration-Resistant Prostate Cancer Patients after Docetaxel.
    Li JR; Chiu KY; Wang SS; Yang CK; Chen CS; Ho HC; Hung CF; Cheng CL; Yang CR; Chen CC; Wang SC; Lin CY; Chang CH; Hsu CY; Ou YC
    Front Pharmacol; 2017; 8():836. PubMed ID: 29213237
    [No Abstract]   [Full Text] [Related]  

  • 16. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
    Vargas C; Kestin LL; Weed DW; Krauss D; Vicini FA; Martinez AA
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):714-24. PubMed ID: 15708249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [CLINICAL OUTCOMES OF ABIRATERONE ACETATE FOR TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER: A RETROSPECTIVE ANALYSIS].
    Hasumi M; Kato M; Otsu A; Muramatsu K; Shimizu N
    Nihon Hinyokika Gakkai Zasshi; 2019; 110(3):177-184. PubMed ID: 32684578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuroendocrine differentiation in castration-resistant prostate cancer: A case report.
    Priftakis D; Kritikos N; Stavrinides S; Kleanthous S; Baziotis N
    Mol Clin Oncol; 2015 Nov; 3(6):1392-1394. PubMed ID: 26807253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Docetaxel, bevacizumab, and androgen deprivation therapy for biochemical disease recurrence after definitive local therapy for prostate cancer.
    McKay RR; Gray KP; Hayes JH; Bubley GJ; Rosenberg JE; Hussain A; Kantoff PW; Taplin ME
    Cancer; 2015 Aug; 121(15):2603-11. PubMed ID: 25903013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
    Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
    Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.